NAC medicine for infants with biliary atresia
Treatments studied
Part of Digestive system, Genetic & congenital clinical trials.
This trial tests whether an oral medicine called N-acetylcysteine (NAC) is safe and well-tolerated in infants with biliary atresia. It looks for participants who are 4–9 months old, can eat and take medicines by mouth, and will stay in the hospital for at least 4 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is between 4 and 9 months old (122 to 273 days of life) when starting the study.
- Your baby has been diagnosed with biliary atresia, confirmed during a special surgery called an intraoperative cholangiogram.
- Your baby can eat and take medicines by mouth (not dependent on a feeding tube).
- Your baby will be in the hospital for at least 4 days during the study.
- You and your family agree to the study plan after understanding the risks and that it is experimental.
- Your baby was born at 32 weeks or later in the pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special nutrition plan helps babies with biliary atresia recover better after Kasai surgery. It is for infants under 3 months old who are ready for surgery.
This study follows babies under 6 months old who have early signs of liver disease (cholestasis) to better understand what causes it and how it progresses. Researchers will collect medical information over time to improve diagnosis and treatment.
This study enrolls children and young adults with biliary atresia (a condition where bile can’t flow properly from the liver) to learn from their care and outcomes over scheduled visits. It may help researchers understand the disease better and improve future treatment.
This trial is studying children who have biliary atresia, a serious liver problem, including some who also have tetralogy of Fallot (a congenital heart condition). It also includes healthy children for comparison, and may help researchers understand the illness and treatments better.
This trial tests whether a special nutritional support formula rich in medium-chain fats can help infants with biliary atresia after the Kasai procedure. It may support feeding and liver recovery during the early months after surgery.
This trial tests if N-acetylcysteine, a medicine that helps the liver and fights inflammation, can improve outcomes for adults with a severe infection and liver stress.
Hear when a new Biliary Atresia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.